# Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone

> **NCT01882361** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 77 (actual)

## Conditions studied

- Opiate Dependence
- Human Immunodeficiency Virus

## Interventions

- **DRUG:** injectable naltrexone
- **DRUG:** placebo comparator

## Key facts

- **NCT ID:** NCT01882361
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2020-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01882361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01882361, "Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01882361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*